Home › Research › Disease mechanisms
Effects of triptolide herb on the progression of Alzheimer's disease preclinical models: a systematic review
Shami R, El Majzoub R, Ismail A, Kotaich J, Kassem M, Safadieh G, Fayyad-Kazan M, Chahine B.. Neurodegenerative disease management, 2025-09-24
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Aim This study aims to systematically evaluate and synthesize preclinical evidence on the neuroprotective effects of Triptolide (Tri) in Alzheimer's disease (AD) models, focusing on its impact on amyloid-beta accumulation, synaptic dysfunction, neuroinflammation, oxidative stress, autophagy, and apoptosis. Introduction AD is the most common cause of dementia, yet current treatments largely target symptoms rather than underlying pathology. Tri, a bioactive compound from Tripterygium wilfordii , has shown promise due to its anti-inflammatory, antioxidant, and neuroprotective properties. Methods A systematic search of PubMed, Embase, and Web of Science was conducted up to 16 March 2024. English-language in vivo and in vitro studies on Tri's effects in AD models were included. Methodological quality was assessed using SYRCLE and SciRAP tools. The review is registered in PROSPERO (CRD42024521822). Results Out of 403 studies, 15 met the inclusion criteria (6 in vivo, 8 in vitro, 1 both). Tri reduced Aβ burden, enhanced memory and synaptic integrity, suppressed neuroinflammation and oxidative stress, and modulated autophagy and apoptosis. Conclusion Tri demonstrates significant multi-target neuroprotective effects in AD preclinical models. Further high-quality studies are warranted to optimize dosing, delivery, and safety for clinical translation.
What this study adds
Evidence grade: Low
This is a pooled review. This review of preclinical research found 15 studies, out of 403 screened, testing triptolide, a compound from the plant Tripterygium wilfordii, in Alzheimer's disease models. In these cell and animal models it reduced amyloid-beta build-up, improved memory and synapse health, and dampened inflammation and oxidative stress.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Shami, R., El Majzoub, R., Ismail, A., Kotaich, J., Kassem, M., Safadieh, G., et al. (2026). Effects of triptolide herb on the progression of Alzheimer's disease preclinical models: a systematic review. Neurodegenerative disease management. https://doi.org/10.1080/17582024.2025.2562776
Vancouver
Shami R, El Majzoub R, Ismail A, Kotaich J, Kassem M, Safadieh G, et al. Effects of triptolide herb on the progression of Alzheimer's disease preclinical models: a systematic review. Neurodegenerative disease management. 2026. doi:10.1080/17582024.2025.2562776. PMID: 40990233.
BibTeX
@article{shami2026-40990233,
author = {Shami, R. and El Majzoub, R. and Ismail, A. and Kotaich, J. and Kassem, M. and Safadieh, G. and Fayyad-Kazan, M. and Chahine, B.},
title = {{Effects of triptolide herb on the progression of Alzheimer's disease preclinical models: a systematic review}},
journal = {Neurodegenerative disease management},
year = {2026},
doi = {10.1080/17582024.2025.2562776},
pmid = {40990233},
url = {https://doi.org/10.1080/17582024.2025.2562776}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Results Out of 403 studies, 15 met the inclusion criteria (6 in vivo, 8 in vitro, 1 both).
- Conclusion Tri demonstrates significant multi-target neuroprotective effects in AD preclinical models.
Why it matters
This review of preclinical research found 15 studies, out of 403 screened, testing triptolide, a compound from the plant Tripterygium wilfordii, in Alzheimer's disease models. In these cell and animal models it reduced amyloid-beta build-up, improved memory and synapse health, and dampened inflammation and oxidative stress. These are lab results, so the authors call for further high-quality studies on dosing, delivery and safety before it could be tried in patients.
Study details
- Study designsystematic review
- Evidence strengthLow
How this study scored 42/100
Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for sample size, effect reported and studied in people because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neurodegenerative disease management) |
| Journal's citation record | 0 / 4 | Neurodegenerative Disease Management: journal h-index 47 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A systematic review of all the studies on the question |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 1 / 6 | Cited 0.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Bahia Chahine: h-index 9 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | American University of Beirut: institution h-index 404 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40990233) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 42 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1080/17582024.2025.2562776
- PubMed: 40990233
- Original source →
- Free full text: PubMed Central →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Disease mechanisms from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.